Amicus Therapeutics, Inc. (FOLD) CEO Sells $165,025.12 in Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO John F. Crowley sold 12,206 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $13.52, for a total value of $165,025.12. Following the transaction, the chief executive officer now owns 340,207 shares of the company’s stock, valued at approximately $4,599,598.64. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of Amicus Therapeutics, Inc. (NASDAQ FOLD) traded up $0.02 during mid-day trading on Wednesday, hitting $13.00. The company’s stock had a trading volume of 1,583,811 shares, compared to its average volume of 3,147,920. Amicus Therapeutics, Inc. has a twelve month low of $4.41 and a twelve month high of $16.60. The company has a debt-to-equity ratio of 0.39, a current ratio of 6.32 and a quick ratio of 6.22.

Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The firm had revenue of $10.90 million during the quarter, compared to analysts’ expectations of $9.02 million. During the same quarter in the prior year, the company posted ($0.33) earnings per share. Amicus Therapeutics’s quarterly revenue was up 419.0% compared to the same quarter last year. equities analysts forecast that Amicus Therapeutics, Inc. will post -1.56 EPS for the current year.

A number of research firms recently issued reports on FOLD. BidaskClub cut Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, December 7th. Zacks Investment Research cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, October 12th. Goldman Sachs Group reiterated a “neutral” rating and issued a $17.00 target price on shares of Amicus Therapeutics in a report on Friday, October 6th. Chardan Capital reiterated a “buy” rating and issued a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Finally, Robert W. Baird reiterated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $17.81.

Several hedge funds have recently modified their holdings of the business. Sage Capital Advisors llc purchased a new stake in shares of Amicus Therapeutics in the 3rd quarter worth $154,000. GSA Capital Partners LLP bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $309,000. Iguana Healthcare Management LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $905,000. Sterling Capital Management LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $218,000. Finally, Neuberger Berman Group LLC bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth $196,000.

COPYRIGHT VIOLATION WARNING: This story was originally published by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/12/13/amicus-therapeutics-inc-fold-ceo-sells-165025-12-in-stock.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Insider Buying and Selling by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply